Armodafinil increased mean sleep latency by 2.0 minutes in patients with associated with obstructive sleep apnea.
Patients receiving armodafinil showed a significant improvement in quality of episodic secondary memory compared to those on placebo.
Armodafinil enhanced patients' ability to engage in activities of daily living compared to the placebo group.
Fatigue levels decreased significantly in patients taking armodafinil compared to those on placebo.
Common adverse events included headache, nausea, and insomnia, but armodafinil did not negatively impact nighttime sleep.
usage remained consistent at approximately 7 hours per night among patients during the study.
Simplified
Residual (ES) and impaired cognition can occur despite effective and regular (nCPAP) therapy in some patients with obstructive sleep apnea (OSA). A pooled analysis of two 12-week, randomized, double-blind studies in nCPAP-adherent patients with ES associated with OSA evaluated the effect of armodafinil on wakefulness and cognition. Three hundred and ninety-one patients received armodafinil (150 or 250 mg) and 260 patients received placebo once daily for 12 weeks. Efficacy assessments included the Maintenance of Wakefulness Test (MWT), Cognitive Drug Research cognitive performance battery, Epworth Sleepiness Scale, and Brief Fatigue Inventory. Adverse events were monitored. Armodafinil increased mean MWT sleep latency from baseline to final visit by 2.0 min vs a decrease of 1.5 min with placebo (P < 0.0001). Compared with placebo, armodafinil significantly improved quality of episodic secondary memory (P < 0.05) and patients' ability to engage in activities of daily living (P < 0.0001) and reduced fatigue (P < 0.01). The most common adverse events were headache, nausea, and insomnia. Armodafinil did not adversely affect desired nighttime sleep, and nCPAP use remained high (approximately 7 h/night). Adjunct treatment with armodafinil significantly improved wakefulness, long-term memory, and patients' ability to engage in activities of daily living in nCPAP-adherent individuals with ES associated with OSA. Armodafinil also reduced patient-reported fatigue and was well tolerated.
Key numbers
2.0 min
Increase in Sleep Latency
Mean change from baseline in sleep latency for armodafinil group.
4.8 to 3.6
Reduction in Global Fatigue
Global fatigue score change from baseline to final visit.
7.2 to 5.8
Reduction in Worst Fatigue
Worst fatigue score in the past 24 hours from baseline to final visit.
Full Text
We can’t show the full text here under this license.
